OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
CARLSBAD, Calif., May 02, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV.
Mr. Massarany is scheduled to present on Wednesday, May 16 at 9:20 a.m. Pacific Time. Interested parties may access a live and archived webcast of the event at ir.genmarkdx.com.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
